Cenegenics Japan Co., Ltd. agreed to acquire 51% stake in Prometheus. Biotech Corporation. from tella, Inc. (JASDAQ:2191) for ¥153 million on December 25, 2020. Cenegenics Japan will acquire 1,530 common shares of Prometheus. Biotech Corporation. The transaction was resolved by the Board of tella, Inc. on December 25, 2020. The transaction is expected to close on December 28, 2020. Cenegenics Japan Co., Ltd. completed the acquisition of 51% stake in Prometheus. Biotech Corporation. from tella, Inc. (JASDAQ:2191) on December 28, 2020. The consideration shall be paid by Cenegenics Japan Co., Ltd. by January 12, 2021.